Literature DB >> 20590740

The effect of intensive glycaemic control on cardiovascular outcomes.

D Hill1, M Fisher.   

Abstract

The relationship between glycaemia and cardiovascular disease remains controversial. For patients with type 1 diabetes in the Diabetes Control and Complications Trial, intensive glycaemic control reduced microvascular outcomes and, on longer term follow-up, a significant reduction in macrovascular events was observed. For patients with recently diagnosed type 2 diabetes, the findings in the United Kingdom Prospective Diabetes Study were similar; intensive glycaemic control reduced microvascular events during the intervention phase of the study, and a reduction in macrovascular events was observed on longer follow-up. More recently, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation study showed a microvascular benefit of more intensive blood glucose control in patients with longstanding diabetes, whereas the Action to Control Cardiovascular Risk in Diabetes study showed harm if this was performed rapidly, with increase in weight, hypoglycaemia and mortality. Collectively, these studies suggest that slow and steady intensive control of glycaemia improves outcomes in people with diabetes, and that to reduce mortality this should be commenced early in the management of patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590740     DOI: 10.1111/j.1463-1326.2010.01199.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  8 in total

1.  Association of fructosamine to indices of dyslipidemia in older adults with type 2 diabetes.

Authors:  Kim E Innes; Terry Kit Selfe; Abhishek Vishnu
Journal:  Diabetes Metab Syndr       Date:  2010-12-30

Review 2.  What do we need beyond hemoglobin A1c to get the complete picture of glycemia in people with diabetes?

Authors:  Rolf Hinzmann; Christof Schlaeger; Cam Tuan Tran
Journal:  Int J Med Sci       Date:  2012-09-29       Impact factor: 3.738

3.  Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.

Authors:  P Blin; R Lassalle; C Dureau-Pournin; B Ambrosino; M A Bernard; A Abouelfath; H Gin; C Le Jeunne; A Pariente; C Droz; N Moore
Journal:  Diabetologia       Date:  2012-01-06       Impact factor: 10.122

4.  Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus.

Authors:  Fang Wei; Xiaolin Sun; Yingxin Zhao; Hua Zhang; Yutao Diao; Zhendong Liu
Journal:  BMC Nephrol       Date:  2016-07-07       Impact factor: 2.388

Review 5.  Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?

Authors:  F Prattichizzo; A Giuliani; V De Nigris; G Pujadas; A Ceka; L La Sala; S Genovese; R Testa; A D Procopio; F Olivieri; A Ceriello
Journal:  Diabetes Obes Metab       Date:  2016-06-22       Impact factor: 6.577

Review 6.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

7.  Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-02-11       Impact factor: 9.951

8.  Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment.

Authors:  Emanuela Orsi; Enzo Bonora; Anna Solini; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Gianpaolo Zerbini; Susanna Morano; Antonio Nicolucci; Giuseppe Penno; Giuseppe Pugliese
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.